Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dacomitinib + Mirdametinib in KRASm NSCLC
NCT02039336Phase 2Completed
- Sponsor
- Netherlands Cancer Institute
- Start
- Apr 2014
- Primary completion
- Aug 2018
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Dacomitinib + Mirdametinib with Standard of Care (2 arms). Primary endpoints: Incidence rate of dose-limiting toxicities at 1.5 years and Progression free survival at 2.5 years. Started Apr 2014; status: completed.
02
Drugs
dacomitinibmirdametinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02039336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02039336.